Blend Composition + Dosage Chart
Blend Composition
The 45 mg vial contains three peptide components at fixed proportions, sourced explicitly by the vial dosage protocol. [7]
| Component | Amount in vial | Concentration once reconstituted |
|---|---|---|
| TB-500 | 25 mg | ~8.33 mg/mL |
| BPC-157 | 10 mg | ~3.33 mg/mL |
| KPV | 10 mg | ~3.33 mg/mL |
| Total | 45 mg | ~15 mg/mL |
Dosage Chart
Once-daily subcutaneous injection using a U-100 insulin syringe. The source gives the titration as a total blend dose per phase; it does not publish a per-component breakdown for each phase the way the related KLOW blend does, so this table shows the total dose only, not a per-peptide split. [7]
| Week(s) | Total blend dose | Units (U-100) | Volume |
|---|---|---|---|
| 1–2 | 500 mcg | ~3.3 u | ~0.033 mL |
| 3–4 | 1,000 mcg | ~6.7 u | ~0.067 mL |
| 5–6 | 1,500 mcg | 10 u | 0.10 mL |
| 7–8 | 2,000 mcg | ~13.3 u | ~0.133 mL |
At 15 mg/mL (15,000 mcg/mL), 1 unit is 150 mcg of the blend; the unit and volume figures above are derived from dividing each sourced total dose by that conversion factor. [7] Extended options exist: a 12-week protocol up to 3,000 mcg (20 u, 0.20 mL), or a 16-week protocol up to 4,000 mcg (~26.7 u, ~0.267 mL). [7] The primary cycle runs 8–16 weeks; the source implies a 2–4 week recovery period is typical for peptide blends but does not explicitly state one for Tri-Heal specifically. [7]
Reconstitution
45 mg vial, mixed to a working concentration before drawing a dose.
Add 3.0 mL of bacteriostatic water to the 45 mg vial to yield a total concentration of approximately 15 mg/mL (15,000 mcg/mL). [7]
Before reconstitution, store the lyophilized vial at −20 °C or below in dry conditions. Once reconstituted, refrigerate at 2–8 °C and avoid repeated freeze-thaw cycles; use within 4 weeks. [7]
How It Works
The literature below is component literature: studies of the three individual peptides in Tri-Heal, not of the blend itself. No published study has tested this specific three-component combination in humans.
TB-500 is a synthetic peptide representing the active region of thymosin beta-4, with the active site identified as the amino acid segment LKKTETQ (positions 17–23 of the parent protein), driving actin-dependent cell migration and wound healing. [2] In a rat model of Achilles tendon injury (32 rats in four groups, dosed intraperitoneally for four weeks), TB-500 alone showed the clearest histopathological and biomechanical result; the study's own results state that "Combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone." [1] See the full TB-500 protocol page on this site for its dedicated dosing and citations.
BPC-157 is a pentadecapeptide (15 amino acids) isolated from human gastric juice, with amino acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val and molecular weight 1419.55 Da, described as an anti-inflammatory agent supporting tissue repair in gastrointestinal, musculoskeletal, and wound contexts. [7] See the full BPC-157 protocol page on this site for its detailed mechanism, pharmacokinetics, and citations.
KPV is the minimal active C-terminal tripeptide sequence of alpha-melanocyte-stimulating hormone (alpha-MSH), with potent anti-inflammatory effects reported via melanocortin-3 receptor (MC3R) agonism. [3] KPV has demonstrated anti-inflammatory potential in murine models of inflammatory bowel disease, [4] and a nanoparticle-based oral delivery formulation of KPV was reported to combine accelerated mucosal healing with reduced inflammation in ulcerative colitis models. [5] A separate study investigated KPV's mechanism through MC3R agonist pathways in human bronchial epithelial cells, in the context of airway inflammation. [6]
No human safety or efficacy data exists for Tri-Heal as a blended product. Individual component data come from in vitro, animal, and limited human pilot studies for each peptide separately; the safety, efficacy, and any pharmacokinetic interaction of this specific three-component combination and titration schedule have not been studied in humans. Tri-Heal, as a named product, is not FDA-approved, has no registration in Drugs@FDA, and has no established prescribing label; its individual components similarly lack FDA approval for any indication. [7] This section describes what the component literature reports; it is not a claim of safety or effectiveness for this blend in human use.
References
Component literature. None of these studies tested the Tri-Heal blend itself.
[1] Effects of BPC-157 and TB-500 on Achilles Tendon Healing in Rats · 2026, PMID 42542926
[2] Doping Control Analysis of TB-500 · 2012, PMID 23084823
[3] Alpha-Melanocyte-Stimulating Hormone and Related Tripeptides · Delgado & Ganea, 2008, PMID 18612139
[4] Melanocortin-Derived Tripeptide KPV Has Anti-Inflammatory Potential in Murine Models of Inflammatory Bowel Disease · 2008, PMID 18092346
[5] Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles · 2017, PMID 28143741
[6] Inhibition of Cellular and Systemic Inflammation Cues in Human Bronchial Epithelial Cells · 2012, PMID 22837805
[7] Tri-Heal overview and 45 mg vial dosage protocol · PeptideDosages